William Jawien, MD
Basic profileCalifornia Cancer Associates for Research and Excellence
William Jawien is an Oncology physician affiliated with California Cancer Associates for Research and Excellence. OpenAlex indexes 5 publications with 287 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7130 N Millbrook Ave
Fresno, CA 937203347
Telephone
559-326-1222Provider last certified this registry record 9 Oct 2025.
Industry payments
60 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202510 payments
- Daiichi Sankyo Inc.Program year202510 payments
- ABBVIE INC.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
61.8%Erythropoiesis-stimulating Agent39.2%Darbepoetin alfa100%Part B, office-administered≥70 patientsIron, parenteral preparations22.5%Ferric carboxymaltose87%Ferric derisomaltose13%Part B, office-administered≥42 patients+ 3 more classes in this area
Cancer & immunology
14.3%PD-1 inhibitor13.7%Nivolumab100%Part B, office-administered≥15 patientsNucleoside Metabolic Inhibitor0.2%Fluorouracil100%Part B, office-administered≥17 patients+ 9 more classes in this area
Metabolism & gastrointestinal
10.7%Substance P/Neurokinin-1 Receptor Antagonist7%Aprepitant100%Part B, office-administered≥31 patientsSerotonin-3 Receptor Antagonist3.3%Granisetron86%Palonosetron hcl13%Ondansetron Odt1%Part D + Part B≥24 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Analysis of potential regulatory effects on gene expression of alu-like repetitive DNA from the 5' flanking region of the bovine parathyroid hormone gene
Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
1987
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”